Treat new onset of type 1 diabetes by decidual stromal cells - Establish rationale for a clinical phase I/II trial
Stem cell-based therapy has achieved positive results for diabetes both in preclinical and clinical trials. The most studied stem cell type in the treatment of diabetes has been mesenchymal stromal cells (MSC). MSC are multipotent stromal cells that show immunomodulatory and anti-inflammatory properties. We have developed a method to isolate MSC from the placenta (DSC). In this project, we aim to investigate the efficiency of DSC to reduce the inflammatory response in beta cells and modulate the immune cells involved in the onset of T1D. We hypothesize that DSC can target the immune- and inflammatory pathways in T1D.